Duchenne and Becker Muscular Dystrophy

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Duchenne and Becker Muscular Dystrophy, Duchenne muscular dystrophy, Muscular Disorders, Atrophic, X-linked disease, hereditary disease, inherited neurodegenerative disorder, muscle tissue disorder, muscular dystrophy, musculoskeletal system disorder, myotonic dystrophy, myotonic syndrome, nervous system disorder, neurodegenerative disease, neuromuscular disease	Recruiting	Phase 3	2026-05-27		NCT07608432

Clinical trials